Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer.

ABSTRACT:

Background

Previous research has shown that stereotactic body radiation therapy (SBRT) can achieve a high level of tumor control in patients with early-stage non-small cell lung cancer (NSCLC). However, to date, such studies have mainly focused on peripheral early-stage patients. This study aimed to assess the clinical outcomes and toxicity of patients with central lung cancer treated with SBRT in our institution.

Methods

A total of 31 consecutive central early-stage NSCLC patients who were treated with SBRT using the biologically effective dose (BED; α/β =10) 100-119 Gy in 4-10 fractions between April, 2013, and August, 2016, were reviewed. The RTOG 0813 trial standard was used to define whether the NSCLC was centrally located. All patients received four-dimensional compute

SUBMITTER: Sun X 

PROVIDER: S-EPMC7481586 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature